Clinical trials
Hepatitis B Virus Infection clinical trials
Below are recruiting hepatitis b virus infection clinical trials, each written for real people, not researchers. We’re tracking 108 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06803368Recruiting
Recovery and maintenance strategies for chronic hepatitis B
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
Beijing, Beijing MunicipalityAges 18–65 - NCT06874127Recruiting
Predicting liver repair in hepatitis B after treatment
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
BeijingAges 18 years+ - NCT06876467Recruiting
Study of immune response to hepatitis B vaccine
This study looks at how your body's cells respond after getting a hepatitis B vaccine. It may help researchers understand how well the vaccine works.
ParisAges 18 years+ - NCT06887036RecruitingPhase 2
Methylene blue for chronic inactive hepatitis B
This trial tests whether a medication called methylene blue can help lower the amount of hepatitis B virus in people with a chronic but inactive infection. It may be an option for people whose virus levels are stable but not fully controlled.
Lugano, Canton TicinoAges 18–79 - NCT06906016Recruiting
New blood tests for hepatitis B
This study looks at new blood tests (biomarkers) to better understand chronic hepatitis B and how it affects treatment decisions. It may help doctors find better ways to manage your condition.
Créteil, CréteilAges 18 years+ - NCT06963710RecruitingPhase 2
New Hepatitis B Treatment vs Standard Drug
This trial tests a new oral medication (ALG-000184) compared to an existing drug (tenofovir) for people with chronic hepatitis B who have not been treated recently. It aims to see if the new drug is better at lowering the virus and improving liver health.
Chandler, ArizonaAges 18–65 - NCT06966908Recruiting
Managing hepatitis B in non-specialty hospital settings
This study looks at how patients with chronic hepatitis B are managed when they visit non-liver clinics. It aims to improve care and may also include a survey about quality of life for those starting treatment.
Guangzhou, GuangdongAges Any age - NCT07079150Recruiting
Long-term pegylated interferon study for HBV families with poor outcomes
This study looks at how well pegylated interferon alpha-2b works over the long term for people with chronic hepatitis B who come from families where the virus has caused serious liver problems like cirrhosis or liver cancer. The goal is to see if this treatment can help prevent these bad outcomes in family members.
Xi'an, ShaanxiAges 18–70 - NCT07137247Recruiting
How the immune system changes over time in chronic hepatitis B
This study tracks how the immune system works in people with chronic hepatitis B who haven't taken antiviral medication in the last 6 months. It aims to understand the natural history of the infection without treatment.
Guangzhou, GuangdongAges 1–80 - NCT07240350Recruiting
Hepatitis B immune response in surgery patients
This study looks at how the body's immune system responds in people with chronic hepatitis B who also need surgery on certain organs. The goal is to learn more about the immune reaction in tonsils, lymph nodes, or other tissues to help find better treatments for hepatitis B.
Guangzhou, GuangdongAges 18–75 - NCT07389044RecruitingPhase 1
Safety study of IB-001 injection in healthy people and hepatitis B patients
This study tests a new injection called IB-001 in two groups: healthy people and people with chronic hepatitis B. The goal is to see if it's safe and how the body handles it at different doses. It might offer a new treatment option for hepatitis B in the future.
ChisinauAges 18–70 - NCT07275554Recruiting
Gene patterns and risk prediction in hepatitis B liver failure
This study looks at how gene changes (methylation) in people with hepatitis B-related liver failure may predict how well they will do. It aims to create a risk score to guide treatment.
Jinan, ShandongAges 18 years+ - NCT07328711RecruitingEarly Phase 1
Immunotherapy for chronic hepatitis B after HBsAg loss
This trial tests an immunomodulatory therapy for people with chronic hepatitis B who have already cleared the surface antigen (HBsAg) with a specific treatment. It aims to understand why some people achieve a cure and how to improve outcomes.
Beijing, Beijing MunicipalityAges 18–60 - NCT07051187RecruitingPhase 1
WGc0201 for chronic hepatitis B
This trial tests a new drug called WGc0201 in adults with chronic hepatitis B who have controlled their virus with standard antiviral pills. It aims to see if WGc0201 can further reduce hepatitis B surface antigen (HBsAg) levels.
Chengdu, SichuanAges 18–65 - NCT07358910Recruiting
Tracking infectious diseases in communities
This study looks at how infections spread in villages in Cambodia. If you live in a participating village, you might help us understand and prevent disease outbreaks.
Phnom Penh, Phnom PenhAges 2–75 - NCT07519330RecruitingPhase 2
Testing HH-006 treatment for chronic hepatitis B
This study tests a new drug called HH-006 to see if it can help treat chronic hepatitis B infection. Participants will be grouped by their infection level, and the study checks whether the drug is safe and works to reduce the hepatitis B virus.
Chongqing, Chongqing MunicipalityAges 18–45 - NCT07542951Enrolling by invitationPhase 4
TAF vs TDF antiviral treatment during pregnancy for hepatitis B
This study compares two antiviral medications (TAF and TDF) in pregnant women with hepatitis B to see which is safer and more effective during pregnancy and for the baby's health.
Guangzhou, GuangdongAges 20–40 - NCT07215871Enrolling by invitationPhase 1
Second H10N7 flu challenge for prior participants
This study tests whether people who have already been exposed to a lab-made H10N7 flu virus can be safely exposed again. It checks how their immune system responds and how long they shed the virus, in a controlled, isolated setting.
Bethesda, MarylandAges 18–55 - NCT07635186RecruitingPhase 2
AHB-137 injection for treatment-naïve chronic hepatitis B
This study tests a new injection called AHB-137 in people with chronic hepatitis B who have never received antiviral treatment. The goal is to see if it can help reduce the hepatitis B virus in the body and improve liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT07709520RecruitingPhase 2
Testing a new hepatitis B treatment in adults
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
BeijingAges 35–65 - NCT06154278RecruitingPhase 2
Testing imdusiran for chronic hepatitis B
This trial tests an injected medication called imdusiran (AB-729) to see how it affects the immune system in people with chronic hepatitis B. It is for people who are already stable on oral antivirals and want to try a new approach to possibly control the virus better.
Baltimore, MarylandAges 18 years+ - NCT06295328RecruitingPhase 1/Phase 2
Terbinafine for chronic hepatitis B: safety and effect
This study tests whether a fungus-fighting drug, terbinafine, can help treat chronic hepatitis B. It is for people with stable disease who are not on other antivirals or are only on tenofovir.
Amsterdam, North HollandAges 18–60 - NCT06853886Recruiting
Genetic study for hepatitis B patients to find new treatment pathways
This study looks at the genes of people with chronic hepatitis B (HBV) to find why some people's immune cells (B cells and NK cells) stop working properly. The goal is to discover new ways to treat the disease.
LimogesAges 18 years+ - NCT07307586RecruitingPhase 3
Azvudine for new hepatitis B patients
This study tests a new pill (azvudine) to see if it can cure chronic hepatitis B in people who have never been treated before. It is for those with active infection and elevated liver enzymes.
Zhengzhou, HenanAges 18–65
Hear when a new Hepatitis B Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis b virus infection?
- Yes. Clin2 currently lists 108 recruiting hepatitis b virus infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis b virus infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis b virus infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.